157 related articles for article (PubMed ID: 8610355)
61. Lung transplantation: the role of azithromycin in the management of patients with bronchiolitis obliterans syndrome.
Fietta AM; Meloni F
Curr Med Chem; 2008; 15(7):716-23. PubMed ID: 18336286
[TBL] [Abstract][Full Text] [Related]
62. The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study.
Chen S; Zhao K; Lin R; Wang S; Fan Z; Huang F; Chen X; Nie D; Du X; Guo Z; Lin D; Xuan L; Xu N; Sun J; Peng Xiang A; Liu Q
EBioMedicine; 2019 Nov; 49():213-222. PubMed ID: 31668569
[TBL] [Abstract][Full Text] [Related]
63. Long-term effect of azithromycin in bronchiolitis obliterans syndrome.
Gan CT; Ward C; Meachery G; Lordan JL; Fisher AJ; Corris PA
BMJ Open Respir Res; 2019; 6(1):e000465. PubMed ID: 31673366
[TBL] [Abstract][Full Text] [Related]
64. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients.
Shitrit D; Bendayan D; Gidon S; Saute M; Bakal I; Kramer MR
J Heart Lung Transplant; 2005 Sep; 24(9):1440-3. PubMed ID: 16143268
[TBL] [Abstract][Full Text] [Related]
65. Bronchiolitis obliterans syndrome after single-lung transplantation: impact of time to onset on functional pattern and survival.
Brugière O; Pessione F; Thabut G; Mal H; Jebrak G; Lesèche G; Fournier M
Chest; 2002 Jun; 121(6):1883-9. PubMed ID: 12065353
[TBL] [Abstract][Full Text] [Related]
66. Physiologic definitions of obliterative bronchiolitis in heart-lung and double lung transplantation: a comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second.
Patterson GM; Wilson S; Whang JL; Harvey J; Agacki K; Patel H; Theodore J
J Heart Lung Transplant; 1996 Feb; 15(2):175-81. PubMed ID: 8672521
[TBL] [Abstract][Full Text] [Related]
67. Assessment of mean transit time in the engrafted lung with 133Xe lung ventilation scintigraphy improves diagnosis of bronchiolitis obliterans syndrome in living-donor lobar lung transplant recipients.
Shinya T; Sato S; Kato K; Gobara H; Akaki S; Date H; Kanazawa S
Ann Nucl Med; 2008 Jan; 22(1):31-9. PubMed ID: 18250985
[TBL] [Abstract][Full Text] [Related]
68. Extended ganciclovir prophylaxis in lung transplantation.
Perreas KG; McNeil K; Charman S; Sharples LD; Wreghitt T; Wallwork J
J Heart Lung Transplant; 2005 May; 24(5):583-7. PubMed ID: 15896756
[TBL] [Abstract][Full Text] [Related]
69. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation.
Davis RD; Lau CL; Eubanks S; Messier RH; Hadjiliadis D; Steele MP; Palmer SM
J Thorac Cardiovasc Surg; 2003 Mar; 125(3):533-42. PubMed ID: 12658195
[TBL] [Abstract][Full Text] [Related]
70. Bronchiolitis obliterans syndrome after lung transplantation: medical treatment.
Verleden GM
Monaldi Arch Chest Dis; 2000 Apr; 55(2):140-5. PubMed ID: 10949876
[TBL] [Abstract][Full Text] [Related]
71. Is transplant operation important in determining posttransplant risk of bronchiolitis obliterans syndrome in lung transplant recipients?
Hadjiliadis D; Davis RD; Palmer SM
Chest; 2002 Oct; 122(4):1168-75. PubMed ID: 12377838
[TBL] [Abstract][Full Text] [Related]
72. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation.
Bergeron A; Chevret S; Chagnon K; Godet C; Bergot E; Peffault de Latour R; Dominique S; de Revel T; Juvin K; Maillard N; Reman O; Contentin N; Robin M; Buzyn A; Socié G; Tazi A
Am J Respir Crit Care Med; 2015 Jun; 191(11):1242-9. PubMed ID: 25835160
[TBL] [Abstract][Full Text] [Related]
73. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation.
Verleden GM; Lievens Y; Dupont LJ; Van Raemdonck DE; De Vleeschauwer SI; Vos R; Vanaudenaerde BM
Transplant Proc; 2009 Jun; 41(5):1816-20. PubMed ID: 19545735
[TBL] [Abstract][Full Text] [Related]
74. Diagnostic value of ventilation/perfusion single-photon emission computed tomography/computed tomography for bronchiolitis obliterans syndrome in patients after lung transplantation.
Nakashima M; Shinya T; Oto T; Okawa T; Takeda Y
Nucl Med Commun; 2019 Jul; 40(7):703-710. PubMed ID: 31022070
[TBL] [Abstract][Full Text] [Related]
75. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
Sato M; Waddell TK; Wagnetz U; Roberts HC; Hwang DM; Haroon A; Wagnetz D; Chaparro C; Singer LG; Hutcheon MA; Keshavjee S
J Heart Lung Transplant; 2011 Jul; 30(7):735-42. PubMed ID: 21419659
[TBL] [Abstract][Full Text] [Related]
76. Proteomic bronchiolitis obliterans syndrome risk monitoring in lung transplant recipients.
Wolf T; Oumeraci T; Gottlieb J; Pich A; Brors B; Eils R; Haverich A; Schlegelberger B; Welte T; Zapatka M; von Neuhoff N
Transplantation; 2011 Aug; 92(4):477-85. PubMed ID: 21716170
[TBL] [Abstract][Full Text] [Related]
77. Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients.
Hohlfeld J; Niedermeyer J; Hamm H; Schäfers HJ; Wagner TO; Fabel H
J Heart Lung Transplant; 1996 Sep; 15(9):888-94. PubMed ID: 8889984
[TBL] [Abstract][Full Text] [Related]
78. Spirometrically significant acute rejection increases the risk for BOS and death after lung transplantation.
Davis WA; Finlen Copeland CA; Todd JL; Snyder LD; Martissa JA; Palmer SM
Am J Transplant; 2012 Mar; 12(3):745-52. PubMed ID: 22123337
[TBL] [Abstract][Full Text] [Related]
79. A review of bronchiolitis obliterans syndrome and therapeutic strategies.
Hayes D
J Cardiothorac Surg; 2011 Jul; 6():92. PubMed ID: 21767391
[TBL] [Abstract][Full Text] [Related]
80. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study.
Gerhardt SG; McDyer JF; Girgis RE; Conte JV; Yang SC; Orens JB
Am J Respir Crit Care Med; 2003 Jul; 168(1):121-5. PubMed ID: 12672648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
